AORT
Price
$28.23
Change
-$0.32 (-1.12%)
Updated
May 22, 02:09 PM (EDT)
Capitalization
873.56M
70 days until earnings call
MYGN
Price
$4.01
Change
-$0.06 (-1.47%)
Updated
May 22, 12:46 PM (EDT)
Capitalization
1.93B
70 days until earnings call
Interact to see
Advertisement

AORT vs MYGN

Header iconAORT vs MYGN Comparison
Open Charts AORT vs MYGNBanner chart's image
Artivion
Price$28.23
Change-$0.32 (-1.12%)
Volume$100
Capitalization873.56M
Myriad Genetics
Price$4.01
Change-$0.06 (-1.47%)
Volume$870
Capitalization1.93B
AORT vs MYGN Comparison Chart
Loading...
AORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AORT vs. MYGN commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AORT is a Buy and MYGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (AORT: $28.55 vs. MYGN: $4.07)
Brand notoriety: AORT and MYGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AORT: 67% vs. MYGN: 102%
Market capitalization -- AORT: $873.56M vs. MYGN: $1.93B
AORT [@Medical Specialties] is valued at $873.56M. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AORT’s FA Score shows that 0 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • AORT’s FA Score: 0 green, 5 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both AORT and MYGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AORT’s TA Score shows that 5 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s).

  • AORT’s TA Score: 5 bullish, 4 bearish.
  • MYGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AORT is a better buy in the short-term than MYGN.

Price Growth

AORT (@Medical Specialties) experienced а -1.48% price change this week, while MYGN (@Medical Specialties) price change was +5.99% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.56%. For the same industry, the average monthly price growth was +7.15%, and the average quarterly price growth was -0.10%.

Reported Earning Dates

AORT is expected to report earnings on Jul 31, 2025.

MYGN is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Medical Specialties (+0.56% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MYGN($1.93B) has a higher market cap than AORT($874M). AORT YTD gains are higher at: -0.140 vs. MYGN (-70.314). AORT has higher annual earnings (EBITDA): 26.8M vs. MYGN (-197.4M). MYGN has more cash in the bank: 141M vs. AORT (58.9M). MYGN has less debt than AORT: MYGN (152M) vs AORT (358M). MYGN has higher revenues than AORT: MYGN (753M) vs AORT (354M).
AORTMYGNAORT / MYGN
Capitalization874M1.93B45%
EBITDA26.8M-197.4M-14%
Gain YTD-0.140-70.3140%
P/E Ratio434.78N/A-
Revenue354M753M47%
Total Cash58.9M141M42%
Total Debt358M152M236%
FUNDAMENTALS RATINGS
AORT vs MYGN: Fundamental Ratings
AORT
MYGN
OUTLOOK RATING
1..100
274
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4297
P/E GROWTH RATING
1..100
742
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AORT's Valuation (94) in the Medical Specialties industry is in the same range as MYGN (97) in the Biotechnology industry. This means that AORT’s stock grew similarly to MYGN’s over the last 12 months.

AORT's Profit vs Risk Rating (73) in the Medical Specialties industry is in the same range as MYGN (100) in the Biotechnology industry. This means that AORT’s stock grew similarly to MYGN’s over the last 12 months.

AORT's SMR Rating (100) in the Medical Specialties industry is in the same range as MYGN (100) in the Biotechnology industry. This means that AORT’s stock grew similarly to MYGN’s over the last 12 months.

AORT's Price Growth Rating (42) in the Medical Specialties industry is somewhat better than the same rating for MYGN (97) in the Biotechnology industry. This means that AORT’s stock grew somewhat faster than MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for AORT (74) in the Medical Specialties industry. This means that MYGN’s stock grew significantly faster than AORT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AORTMYGN
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGOTX15.45N/A
N/A
Goldman Sachs Mid Cap Growth Inv
MFLLX15.82N/A
N/A
Morgan Stanley Inst Inception R6
QUAZX69.80N/A
N/A
AB Small Cap Growth Z
TRHZX156.44N/A
N/A
T. Rowe Price Equity Index 500 Z
RLUSX16.25-0.30
-1.81%
Lazard US Equity Focus R6

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-8.54%
WAT - MYGN
39%
Loosely correlated
-4.07%
ATEC - MYGN
34%
Loosely correlated
-2.39%
ICUI - MYGN
31%
Poorly correlated
-3.09%
VCYT - MYGN
31%
Poorly correlated
-4.17%
AORT - MYGN
31%
Poorly correlated
-2.13%
More